A single product candidate that provides clinical benefit across multiple indications and patient populations allows more conditions to be treated quicker, resulting in more efficient research and development for sponsors. However, developing these types of products is not without its challenges. Sponsors that strategically plan for Investigational New Drug (IND) management can maximize limited resources, simplify activities surrounding IND maintenance, and ensure IND holders comply with required responsibilities.
In this white paper, you will learn:
- Benefits of consolidating general information into one place and aligning dates to streamline reporting
- Pediatric requirements to consider early in the development process
- Possible labeling scenarios and requirements
- Opportunities for accelerating development and eventual approval
5 Ways Regulatory Strategists Increase Your Chance of Product Approval
There’s an old adage: “Plan your work, then work your plan.” This statement is never more valid than in the area of regulatory strategy. Regulatory…
Brexit and the New Regulatory Environment
The UK formally left the EU on 31 January 2020, followed by an 11-month transition period which ended on 31 December 2020. On 01 January 2021, the…
Basics of Regulatory Strategy
Driving development of drug products from pre-IND through marketing.